U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07444892) titled 'Levodopa for Diabetic Retinopathy' on Feb. 25.
Brief Summary: The purpose of this study is to determine optimum dosing strategies of levodopa and determine the physiologic mechanisms that provide the therapeutic response to restore abnormalities in the electrical conductivity of the retina in people with diabetes and no clinically visible retinopathy.
Study Start Date: April 18, 2022
Study Type: INTERVENTIONAL
Condition:
Diabetic Retinopathy
Intervention:
DRUG: Levodopa
Patients will receive tablets of generic 25 mg carbidopa/100 mg levodopa as the drug treatment.
DRUG: Placebo
Patients will receive matching placebo tablets...